The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism
Abstract
Combined hormonal oral contraceptives (OCs) may lead to a mild rise in blood pressure and body weight. In rare instances, large increments in blood pressure are measured. We investigated the effect of a combination of ethinyl estradiol (EE) plus a progestogen with antimineralocorticoid, i.e. natriuretic, properties [Drospirenone (DRSP)] on body weight, blood pressure, the renin-aldosterone system, atrial natriuretic factor, plasma lipids, and glucose tolerance. It is anticipated that this will lead to the development of an OC that does not raise body weight or blood pressure. Four groups of 20 women each received 30 micrograms EE plus 3 mg DRSP (group A), 20 micrograms EE plus 3 mg DRSP (group B), 15 micrograms EE plus 3 mg DRSP (group C), and, as a control OC, 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, Schering; group D) for 6 months. During the OC-free control cycles before and after treatment and throughout treatment, the target parameters were measured. Between the pretreatment cycle and the sixth treatment cycle, mean body weight fell by 0.8 to 1.7 kg in groups A, B, and C (P < 0.05 vs. D), whereas it rose by 0.7 kg in group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in groups A, B, and C (significant for A and C vs. D) and increased by 1-2 mm Hg in group D. Renin substrate rose equally in all groups (P < 0.05), whereas PRA and plasma aldosterone rose significantly only in the DRSP groups, presumably due to sodium loss. In the DRSP groups, high density lipoprotein cholesterol rose (P < 0.05), in contrast to group D. Low density lipoprotein cholesterol fell slightly (P > 0.05), whereas triglyceride levels showed a stronger increase in the DRSP groups (P < 0.05) than in group D. All groups attained good cycle control; group A had the best. Side-effects were minimal. To our knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure. It may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
OELKERS, W., SCHÖNESHÖFER, M., & BLÜMEL, A. (1974) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-39-5-882 · Cited by 106
Self-citationEffect of four combined oral contraceptives on blood pressure in the pill-free interval
Nichols, M., Robinson, G., Bounds, W., Newman, B., & Guillebaud, J. (1993) · Contraception · doi:10.1016/0010-7824(93)90034-5 · Cited by 57
Cited by
Gravholt, C. H., Andersen, N. H., Conway, G. S., Dekkers, O. M., Geffner, M. E., Klein, K. O., Lin, A. E., Mauras, N., Quigley, C. A., Rubin, K., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-17-0430 · Cited by 1,101
van Hylckama Vlieg, A., Helmerhorst, F. M., Vandenbroucke, J. P., Doggen, C. J. M., & Rosendaal, F. R. (2009) · BMJ · doi:10.1136/bmj.b2921 · Cited by 666
Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure
Oelkers, W. K. H. (1996) · Steroids · doi:10.1016/0039-128x(96)00007-4 · Cited by 333
Self-citationThe etiology, biology, and evolving pathology of premenstrual syndromes
Halbreich, U. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(03)00097-0 · Cited by 306
Contraceptive hormone use and cardiovascular disease
Shufelt, C. L., & Bairey Merz, C. N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.042 · Cited by 287
Metadata
- Authors
- Oelkers, W.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-06-01
- Volume
- 80
- Issue
- 6
- Pages
- 1816-1821
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2017854872
- Cited by
- 246
- References
- 3
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. https://app.cochat.ai/papers/10.1210/jc.80.6.1816
- The paper
- Oelkers, W. (1995). Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.80.6.1816
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.